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Differential significance of early surgical
complications for acute and long-term
recurrence-free survival following surgical resection
of hepatocellular carcinoma: do comorbidities play
a role?
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Mark op den Winkelb, Christoph Trummc, Martin K. Angelea, Markus Gubaa, Jens Wernera and Markus Rentscha
Background Postoperative complications of Clavien–Dindo grade 3 or more are of prognostic significance in patients who
undergo liver resection for hepatocellular carcinoma (HCC). However, perioperative mortality and patient comorbidities represent
relevant factors that interfere with postoperative long-term survival. To clarify this, a retrospective single-center study was
carried out.
Patients and methods Patient data were prospectively collected in a continuously updated liver resection database. Overall,
184 consecutive patients who underwent liver resection for HCC with a curative intent between March 2003 and December 2013
were selected for the study. The patients were assigned to two groups according to the presence or absence of postoperative
complications. Pre-existing comorbidities, perioperative mortality, surgical outcome, and long-term survival data were analyzed.
Results Postoperative complications requiring revision surgery were identified in 17.4% of the patients. The in-house mortality
rate was 4.8%. Compared with patients without complications, patients with complications were older and had significantly more
pre-existing comorbidities, more advanced tumors, more intrahepatic metastasis, longer operation times, greater blood loss, and
more extensive resections. The overall 5-year survival rates were 40.1 and 52.5% in patients with or without postoperative
complications, respectively. The corresponding 5-year recurrence-free survival rates were 46.3 and 46.7% (perioperative
mortality excluded). Multivariate analysis showed that elevation of the Charlson Comorbidity Index was associated independently
with decreased overall and recurrence-free survival.
Conclusion In patients with HCC, posthepatectomy complications are confirmed to have predictive value. However, closer
analysis and exclusion of perioperative mortality effects show an independent impact of pre-existing comorbidities on long-term
overall und recurrence-free survival. Eur J Gastroenterol Hepatol 29:1045–1053
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Surgical resection represents one of the curative treatment
options for hepatocellular carcinoma (HCC) [1,2].
Multidisciplinary treatment of HCC, frequently in asso-
ciation with hepatic surgery, has significantly improved the
survival rate of HCC patients [3,4]. However, a cure is still
difficult to achieve because recurrence rates of HCC
remain high [5,6]. Nevertheless, despite improved surgical
techniques and perioperative management, mortality and
morbidity rates following hepatectomy for HCC remain
the highest among abdominal surgical procedures [7–10].
Recently, the adverse effects of postoperative complica-
tions on long-term survival after resection were determined
in HCC patients in studies from Japan and Hong Kong
[11–14]. In these studies, the overall perioperative com-
plications impacted survival. However, perioperative
complications were inconsistently defined and the sig-
nificant effects on recurrence-free survival were repealed
when different grades of the Clavien–Dindo classification
were analyzed separately [13,14]. Furthermore, perio-
perative complications may have a strong correlation with
pre-existing comorbidities [15,16]. Other studies identified
age and perioperative blood loss as independent risk fac-
tors [17,18], which have been indirectly linked to recur-
rence of malignancy in various cancers [19]. Beyond this,
the pathogenesis of HCC in the Asian population might
not reflect the common HCC disease triggers in Europe
[20,21]. Whereas in Asia, infection ratios with hepatitis
B or C in patients with HCC uniformly exceed 50%,
nutritive risk factors, including alcohol intake, may
represent the main triggers for cirrhosis and HCC
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particularly in Europe. Nutritional adverse effects may not
only exclusively affect the liver but also other organ sys-
tems, thus increasing the general perioperative risk
[22,23]. This may have long-term implications as these
differences in pathogenesis may result in regional dis-
parities in terms of comorbidity in patients requiring sur-
gery for HCC.
We therefore evaluated the risk of perioperative com-
plications in relation to hepatic surgery for HCC with a
special focus on preoperative comorbidities and the impact
of both factors on long-term general and cancer-free sur-
vival. Different from previous studies, the effects of com-
plications in general, complication grades 3 and 4, and
only grade 4 were analyzed separately. This study provides
insights into particular differences in survival and
recurrence-free survival in relation to the severity of the
complications in a representative Central European surgi-
cal center patient population.
Patients and methods
Patient characteristics and preoperative assessment
From January 2003 to December 2012 (10 years), a total of
1396 liver resections were performed at the Department of
Surgery, Munich University Hospital, Campus Grosshadern
(Munich, Germany). Among these, 184 patients (56 women
and 128 men) underwent hepatic resection for HCC, who
were all included in this study. The mean age was
63.7±0.9 years (median: 66, range: 16–84 years). Follow-up
was continued until June 2016, resulting in a mean follow-up
duration of 3.5 years (median: 2.7 years). Curative resection
(R0) was defined as complete removal of tumor as defined by
pathologic examination. The following clinical variables
were assessed: age; sex; BMI; obesity; comorbidity scores
(see below); pre-existing cardiac or pulmonary diseases;
laboratory parameters: serum α-fetoprotein, creatinine, bilir-
ubin, international normalized ratio, alkaline phosphatase,
γ-glutamyl transferase, alanine aminotransferase, aspartate
aminotransferase; liver-specific risk factors: hepatitis B and
hepatitis C seropositivity, alcohol abuse, steatosis, hepatic
steatosis (including nonalcoholic fatty liver disease), liver
fibrosis, liver cirrhosis; oncologic prognostic variables: num-
ber of lesions, less than one lesion, pTNM stage; perioperative
data: type of surgery, duration of surgery, blood loss, liver
specimen volume; postoperative complications: complications
not related to surgery, hepatic dysfunction, biliary leak,
bilioma (without persistent leak), abscess, hemorrhage, bowel
obstruction, and septic and infectious complications; and
outcome measures: surgical revision, HCC recurrence, overall
survival, and recurrence-free survival.
The Charlson Comorbidity Index (CCI, Supplementary
Table 1, Supplemental digital content 1, http://links.lww.
com/EJGH/A196; [24]) predicts the 1-year mortality
for a patient who may have a range of comorbid
conditions, and may represent a more precise estimate of
the general health status than the American Society of
Anesthesiologists (ASA) classification [25]. The liver-
specific risk was quantified by calculation of the Model
for End-Stage Liver Disease (MELD) score [26]. As the
vast majority of patients had Child Pugh stage A liver
cirrhosis (see below), the Child score was not included in
any analysis.
Surgical technique and procedures
None of the patients required intraoperative ablation
therapy such as ethanol injection or radiofrequency abla-
tion. In general, at our center, local ablation therapy in
connection with hepatic resection (therapeutic splitting) is
performed using interventional radiology, which was not
required among the analyzed cohort.
Assessment of perioperative morbidity and mortality
Postoperative complications within 1 month of hepa-
tectomy included liver-specific complications. The types of
complications and frequency are listed in Table 1. Grade 3
hyperbilirubinemia and prolonged prothrombin time/
international normalized ratio on postoperative day 5
were defined as liver dysfunction according to the criteria
of the International Study Group of Liver Surgery [27].
As the accuracy of the definition of complications has
been inconsistent in previous studies and conclusions are not
easy to draw in terms of all complications, we grouped
postoperative complications into three separate categories
corresponding to a stepwise narrowing of the Clavien–Dindo
grades of complication.
Besides the general occurrence of complications (corres-
ponding to grades 2–5), those fulfilling the criteria of
Clavien grades 3 and 4 complications and the subgroup of
patients who needed surgical revision were separately
registered and statistically evaluated (Fig. 1). All in-house
fatal postoperative clinical courses were classified as grade
5 complications.
Surgical procedures and patient selection
Surgical resection for HCC was considered according to
our center’s algorithm adopted from the Barcelona Clinic
Liver Cancer algorithm for the treatment of HCC [2,28].
Table 1. Overview of postoperative complications
Type of complication n
Liver specific
Hepatic dysfunction 16
Biliary leak or bilioma 11
Biliary tract stenosis 1















Pulmonary embolism (hemodynamically irrelevant) 5
Pleural effusion/seropneumothorax 9
Renal dysfunction 7
Cardiac arrhythmia/ myocardial infarction 8/1
Neurological dysfunction 4
Others (nausea, vomiting, diarrhea) 7
Total 173
Note: more than one complication could be registered in each patient; the list does
not show the severity of the complications.
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In simple terms, technically resectable single tumors (≤5 cm)
in patients with Child A liver cirrhosis were considered to be
surgically removed. Special attention was paid to rule out
uncontrollable ascites or bilirubin serum levels above
2mg/dl before surgery. This rule was slightly modified in the
case of individual therapeutic approaches. No special func-
tional tests were performed before surgery. Surgical access
was achieved by a right-sided J-shaped incision, followed by
slow and gentle hepatic dissection using an ultrasonic dis-
sector with a coagulator (Integra, Plainsboro, New Jersey,
USA or Söring, Quickborn, Germany) and systematic liga-
tion of all sizable vessels under close ultrasonographic gui-
dance along the transection line. Intraoperative vascular
control was achieved using the Pringle maneuver.
Follow-up and assessment of tumor progression
Every patient undergoing liver surgery at our center is
registered in a specially designed database (Filemaker,
Santa Clara, California, USA). From this database, all
patients with a diagnosis of HCC undergoing surgical
therapy were extracted. From the original 195 patients, 11
were excluded from further analysis as the surgical man-
euver was interrupted with or without probe excision for
various reasons. Patient data are maintained continuously
by the documentation department of our clinic. In the
years 2013 and 2016, all patients alive received a ques-
tionnaire or were interviewed by telephone about their
current health status, evidence of tumor recurrence and
subsequent diagnostic procedures, and eventually follow-
up therapy in the case of recurrence. All data registration
was approved by the local ethics committee of the Munich
University Hospital.
Statistical analysis
Comparisons between groups were performed using stan-
dard univariate tests: Student’s t-test for analysis of para-
metric data (after regular rank transformation when
indicated by Shapiro–Wilk statistics) and χ2-test for
nonparametric data.
The Kaplan–Meier method and log-rank testing were
used to determine differences in survival between the
groups (univariate testing). Independent factors increasing
the likelihood of revision surgery were estimated using a
logistic regression model, including the variables age, sex,
liver parenchyma injury (including cirrhosis, fibrosis and
steatosis) (yes/no), ‘Charlson Comorbidity Index’, ‘MELD
score’, ‘ASA score’, ‘BMI’, resection volume (> /<500ml),
‘operation time’, and ‘intraoperative blood loss’.
For the identification of specific risk factors of survival
and recurrence-free survival, a Cox proportional hazards
model was used, including the variables ‘postoperative
complication’, ‘complication Clavien grades 3 and 4’,
‘surgical revision’, ‘septic complications’, ‘Charlson
Comorbidity Index’, ‘MELD score’, ‘ASA score’, ‘BMI’,
and ‘intraoperative blood loss’, which were entered into
the mathematic model using the backward stepwise Wald
method. All calculations were carried out using IMB SPSS,
version 23.0 (IBM SPSS Inc., Armonk, New York, USA).
Results
Patient characteristics and general data
In our patients, a total of 173 complications of different
grades of severity (Clavien–Dindo grades 1–4b) were
registered. Postoperative mortality was 4.8% (grade 5
Fig. 1. Study design algorithm. Patients’ data were analyzed in two steps after stratification of the different grades of complications: (i) all complications,
(ii) complications requiring any reintervention, and (iii) complications requiring revision surgery. First, the overall survival of the complete cohort was analyzed
(n=184). Second, overall and recurrence-free survivals were evaluated after elimination of the perioperatively deceased patients (n=175). HCC, hepatocellular
carcinoma; N, no; OS, overall survival; R-FC, recurrence-free survival; Y, yes.
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complication). In all, 51 patients had grades 3 and 4
complications. Of these, 20 patients were managed by an
endoscopic and/or a radiologic intervention, and 31
(17.4%) required surgical revision (subgroup of grades 3
and 4). The mean time in intensive care was
2.79 ±0.55 days (median: 1, range: 0–62 days). An over-
view of the complications is presented in Table 1. Most
frequently, postoperative ascites, bowel obstruction, and
minor infectious complications were registered; however,
these were managed conservatively. From clinical experi-
ence, factors specific to hepatic surgery were considered
most relevant to the clinical course and the potential need
for revision surgery; these include hepatic dysfunction
(8.7% of all patients), biliary leak (3.3%), bilioma without
leak (2.7%), perihepatic abscess (3.8%), postoperative
hemorrhage (3.8%), sepsis and unspecific infections
(14.6% each), and small bowel obstruction (6.5%).
In all, 45% of our patients experienced tumor recur-
rence during the observation period. Time to recurrence
was 16.2 ± 1.9 months (range: 1–58.5 months). Of these,
15.2% underwent a second surgery at our center for
recurrent HCC. Malignancy-associated death in the
observation period occurred in 28.8%.
Besides the risk of surgery and associated factors
underlying a complicated course after hepatic surgery, a
relevant spectrum of patient-associated comorbidities was
noted in our patient cohort. These were indicated by an
average ASA score of 2.72 ± 0.04 (median: 3, range: 2–4)
and a CCI of 7.2 ± 0.14 (median: 7, range: 3–12).
Furthermore, impaired liver function was indicated by a
score of 7.72 ±0.18. The average BMI was 26.5 (mean:
26.3, range: 18–38.6), indicating overweight in a relevant
subgroup of our patients. Obesity was registered as a
diagnosis in the medical history of 61% of the patients.
Liver-specific diagnoses in the patients’ medical history
with potential alteration of the hepatic tissue and thus
increased risk of surgery were alcohol abuse (24%),
hepatic steatosis (60.7%), fibrosis or cirrhosis (60.7%),
hepatitis B (13%), and hepatitis C (15.8%).
Histopathologic results and perioperative data
A total of 117 HCC were stage I according to the TNM
classification, and 28, 33, and six tumors were stage 2, 3,
and 4, respectively. A reliable lymph node count was
achieved in 104 patients. Of the total, 34 (32.7%) patients
were lymph node positive and 31 patients had positive
resection margins [21 (11.9%) R1, 10 (5.6%) R2]. R2
situations included macroscopic tumor as nonresectable
remnant in vascular proximity or as nonresectable satellite
to be treated by a radiologic intervention or radiotherapy.
An overview of the types of hepatic resections in the two
subgroups of patients with and without complications is
shown in Table 2. The mean duration of the surgical
procedures was 170.4 ± 5.1 min (range: 25–347min), with
a mean blood loss of 984.2 ±102.4 ml (0–7500ml).
Differences in patient characteristics according to grades
of complication
An analysis of the perioperative patient characteristics after
stratification into the three different comparison models
[(i) overall complications (yes/no), (ii) Clavien–Dindo grades
3 and 4 complications (yes/no), and (iii) surgical revision
(yes/no)] yielded similar results. However, neither pre-
operative medical history parameters (i.e. liver parenchyma
alteration, obesity) nor clinical chemistry parameters were
correlated with the risk of complication as shown in Table 3.
The sole exception were serum levels of bilirubin and
aspartate aminotransferase, which were uniformly sig-
nificantly elevated in all subgroups with complications
(P<0.05). However, the comparisons (Table 3) clearly
showed that patients with complications were older and had
higher comorbidities as assessed by the ASA score, the CCI,
and the MELD score. It is noteworthy that this difference
was equal when the following subgroups were analyzed: all
complications, all complications treated with intervention or
repeat surgery, and complications requiring surgical revision.
Predictors of postoperative complications
By means of a logistic regression model, predictors of
postoperative complications were determined. Significant
factors associated with adverse surgical outcome were age
at the time of surgery and intraoperative blood loss, which
were uniformly associated with an increased probability of
overall as well as Clavien–Dindo grades 3 and 4 compli-
cations, as well as requirement of surgical revision
(Table 4).
Survival following resection
Overall survival following surgical resection of HCC was
68.6% after 1 year, 52.4% after 3 years, and 40.1% after
5 years when patients developed complications. This was a
significantly lower survival rate than in those without
complications (1 year: 89.7%, 3 years: 69.6%, 5 years:
52.5%) (Fig. 2a). Restriction of the analysis to
Clavien–Dindo grades 3 and 4 complications and to
complications requiring surgical revision reconfirmed this
difference. Corresponding survival rates were 57.2 versus
88.8% (1 year), 45.6 versus 67.8% (3 years), and 42.1
versus 48.7% (5 years) comparing Clavien–Dindo 3 and 4
versus lower grade (0–2) complications (Fig. 2b). When
complications requiring surgical revision were compared
with all other patients, this difference was even more
pronounced [50.0 vs. 85.6% (1 year), 32.7 vs. 66.9%
(3 years), and 16.4 vs. 50.0% (5 years); P<0.0001]
(Fig. 2c). However, these data showed one important
aspect of the survival analysis. Most of the deceased
patients in this analysis died in the very early days after
surgery or onset of the complication. This led us to analyze
the above subgroups after exclusion of perioperatively
deceased patients (n= 9), which abolished the significant
difference in survival between the complication groups and
those with no complications in all comparisons; however,
a difference by trend remained. The 1-year, 3-year, and
5-year survival was then 77.7, 59.4, and 45.4%, respec-
tively for all complications (Fig. 3a), 70.8, 56.4, and
52.1%, respectively for Clavien–Dindo grades 3 and 4
(Fig. 3b), and 73.7, 48.2, and 24.1%, respectively for
surgical revision only (Fig. 3c).
Recurrence-free survival was likewise analyzed without
the perioperatively deceased patients (Fig. 4). It was worse in
all comparisons; however, no significant differences were
noted when analyzing patients with or without post-
operative complications by the log-rank test (1 year: 75.6 vs.
79.3%; 3 years: 48.9 vs. 63.2%; 5 years: 46.3 vs. 47.4%).
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Equally, on comparing the cohorts with and without
Clavien–Dindo grades 3 and 4 complications, the difference
was not significant (64.1 vs. 81.2%; 50.8 vs. 61.6%; and 36.
vs. 42.9), which was confirmed by analyzing the groups with
or without surgical revision (67.7 vs. 78.2%; 54.1 vs.
59.5%; and 27.1 vs. 42%).
Factors affecting long-term recurrence-free survival
For estimation of independent determinants of long-term
survival, a Cox proportional hazards model including the
most relevant variables identified in univariate statistics
was used. Table 5 shows the results of the analysis carried
out after exclusion of perioperatively deceased patients.
This model showed the CCI to be a significant factor
affecting overall and recurrence-free survival.
It is noteworthy that if the factor age was included as a
continuous variable in the statistical model, as opposed to
a categorized variable as part of the CCI, it significantly
affected long-term overall and recurrence-free survival
(P< 0.05) (Rentsch M, unpublished data).









34 (1) 32 (8)
Segmentectomy 16 21
Central resection (segments 4/5/8) 5 2
Left lobectomy (segments 2/3) 5 11
Left hemihepatectomy 3 10
Right hemihepatectomy 22 6
Extended right hemihepatectomy 4 4
Table 4. Logistic regression model of predictive factors for
postoperative complications
95% Confidence interval
Variables P Exp (β) Lower limit Upper limit
Liver parenchyma injury 702 0.850 702 1.960
sex 0.583 1.280 0.531 3.087
BMI 0.473 1.036 0.941 1.140
Resection volume <500ml 0.463 0.714 0.291 1.755
MELD 0.330 1.072 0.932 1.234
Operation time 0.269 1.003 0.998 1.009
Charlson Comorbidity Index 0.225 1.153 0.916 1.450
Age 0.007 1.051 1.013 1.090
Intraoperative blood loss (ml) 0.008 1.000 1.000 1.001
MELD, Model for End-Stage Liver Disease.
Table 2. Comparisons of complication according to different grades of severity (and corresponding Clavien –Dindo grading)
Comparisons of complication according to different grades of severity (and corresponding Clavien–Dindo grading)
All complications
(corresponding to grades 1–5)
Complications with reintervention
(corresponding to grades 3 and 4)
Complications with surgical revision
(subgroup of grades 3 and 4)
Variables Yes (n=90) No (n=94) P value Yes (n=52) No (n=132) P value Yes (n=32) No (n=152) P value
Sex (women/men) 63/27 65/29 1.0 16/36 40/92 1.0 7/25 49/103 0.29
Age (years) 65.6 61.9 0.02 68.3 ±1.4 63.2 ±1.3 0.006 69.5 ±1.3 62.5 ±1.0 0.01
ASA 2.82 ± 0.04 2.61 ±0.05 0.003 2.90 2.65 0.003 2.91 ±0.07 2.68 ±0.04 0.01
Charlson Index 7.5 ± 0.2 6.8 ±0.2 0.019 7.7 ±0.2 7.0 ±0.17 0.01 7.9 ±0.28 7.0 ±0.15 0.02
BMI 26.8 ± 0.4 26.1 ±0.4 0.25 27.1 ±0.5 26.1 ±0.34 0.10 27.1 ±0.7 26.3 ±0.3 0.29
MELD 8.2 ± 0.3 7.2 ±0.2 0.001 8.31 ±0.42 7.49 ±0.2 0.02 8.34 ±0.51 7.6 ±0.2 0.04
Alcohol
consumption
16 8 0.1 7 17 0.55 5 19 1.0
Steatosis 56 55 1.0 35 76 0.11 23 88 0.1
Fibrosis 35 37 1.0 19 53 0.73 12 60 1.0
Cirrhosis 41 39 0.76 25 55 0.51 14 66 1.0
Hepatitis B 12 12 1.0 8 16 0.63 6 18 0.38
Hepatitis C 17 12 0.31 8 21 1 5 24 1.0
Obesity 56 52 0.76 37 71 0.13 23 85 0.23
Creatinine (mg/dl) 1.07 ± 0.03 1.03 ±0.04 0.068 1.04 ±0.03 1.06 ±0.04 0.36 1.07 ±0.03 1.05 ±0.03 0.13
Bilirubin (mg/dl) 1.13 ± 0.11 0.84 ±0.07 0.014 1.26 ±0.2 0.88 ±0.06 0.002 1.17 ±0.16 0.95 ±0.73 0.02
INR 1.09 ± 0.01 1.06 ±0.01 0.049 1.09 ±0.01 1.07 ±0.01 0.11 1.09 ±0.16 1.07 ±0.01 0.2
ALAT (mg/dl) 76.8 ± 10.7 56.5 ±7.5 0.15 76.2 ±18 62.5 ±5.4 0.86 94.5 ±25.4 60.5 ±4.7 0.88
ASAT (mg/dl) 94.6 ± 14.2 67.1 ±9.7 0.021 103.2 ±19.9 73.1 ±9.1 0.02 117.3 ±27.5 72.7 ±8.4 0.04
γ-GT (mg/dl) 167.8 ± 18.7 132.3 ±13.6 0.15 166.9 ±24.9 143.5 ±12.9 0.43 137.5 ±20.7 152.8 ±13.5 0.97
AP (mg/dl) 131.0 ± 12.5 112.9 ±7.4 0.14 126.7 ±9.2 120.6 ±9.5 0.17 127.2 ±12.0 121.3 ±8.4 0.17
>1 Tumor location 24 19 0.38 14 29 0.56 9 34 0.50
Stage T3/4 21 18 0.71 14 25 0.2 8 31 0.45
N+ 17 17 1.0 9 25 0.8 4 30 0.76
R+ 18 13 0.32 11 20 0.4 4 27 0.61
AFP elevation
(above normal)
33 42 0.62 17 52 1.0 10 59 1.0
Blood loss (ml) 1293 ± 175 681 ±99 0.02 1401 ±235.8 814.5 ±104.5 0.02 1381 ±285.9 898.3 ±107.3 0.04
Operation time
(min)
182.5 ± 7.7 158.7 ±6.5 0.02 182 ±10.3 165.5 ±5.9 0.08 178.2 ±13.9 168.7 ±5.5 0.45
Volume liver
specimen (ml)
439.6 ± 50.1 355.9 ±44.9 0.27 487.8 360.7 0.06 512.4 ±86.5 372.7 ±36.3 0.1
HCC recurrence 44 40 0.74 22 62 0.29 10 79 0.04
Note: numbers indicate either the total number of patients or the mean ±SEM.
AFP, α-fetoprotein; ALAT, alanine aminotransferase; ALST, aspartate aminotransferase; AP, alkaline phosphatase; ASA, American Society of Anesthesiologists;
HCC, hepatocellular carcinoma; INR, international normalized ratio; γ-GT, γ-glutamyl transferase; MELD, Model for End-Stage Liver Disease.
N+, node-positive tumor; R+, tumor-positive resection margin.
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Discussion
The present study investigated the impact of surgical
complications on long-term overall as well as recurrence-
free survival in a patient cohort with HCC over a 10-year
period at a single center. Our study in part confirms pre-
vious observations from Japan, which showed a clear
correlation between early postoperative complications
following hepatectomy and recurrence-free survival for
HCC [12–14] in single-center and multicenter analyses.
The present study, however, is the first to address the long-
term effects of postoperative complications on overall and
recurrence-free survival in a Central European cohort.
Fig. 2. General survival of the complete cohort: perioperative mortality
included. Kaplan–Meier plots of overall survival comparing the groups with or
without complications at all (a), with our without complication grades 3 and 4
according to the Clavien–Dindo classification (b), and comparing those
requiring revision surgery or not (c). Dashed curve: patients without com-
plications; solid curve: patients with complications.
Fig. 3. General survival of the complete cohort: perioperative mortality
excluded. Kaplan–Meier plots of overall survival comparing the groups with
or without complications at all (a), with our without complication grades 3 and
4 according to the Clavien–Dindo classification (b), and comparing those
requiring revision surgery or not (c). Dashed curve: patients without com-
plications; solid curve: patients with complications.
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Besides liver transplantation as the superior form of treat-
ment, surgical therapy represents an accepted curative ther-
apeutic approach to HCC treatment [2,3]. Nevertheless, a
substantial ratio of patients in Europe have to be considered for
resection instead of transplantation because of the well-known
donor organ shortage and patient-sided contraindications for
transplantation [1,2]. Despite substantial improvements in liver
surgery, patient selection, and preoperative conditioning, and
the development of new surgical strategies and techniques
[7–10,29], morbidity and mortality remain high. In the present
study, a meticulous search for complications was performed on
the basis of patients’ files, which resulted in an overall com-
plication rate of 48%, similar to other single-center studies
[12,13]. At first glance, this rate seems high; however, not all
complications may have an impact on survival. Complications
Clavien–Dindo grades 3 and 4 occurred in 28%; however,
one-third of these complications were managed by a radiologic/
endoscopic intervention, whereas 17% required revision sur-
gery. The number of complications Clavien–Dindo grades 3
and 4 in the Japanese multicenter study was 17.1% whereas
the two other studies reported a perioperative mortality of 4.5
and 7%, respectively [12–14].
Thus, we analyzed the effects of complications in our cohort
using the three different comparison models mentioned above.
In doing so, we searched for different effects of the severity of
complications on long-term survival. This was motivated by
the assumption that complications managed conservatively
may be less harmful than those treated by reintervention and/or
revision surgery. This idea has been described in the second-hit
concept of revision surgery [30,31].
For perioperative data, no considerable difference from
previous reports was detected in terms of type of resection,
intraoperative blood loss, surgery time, and pathologic
criteria [11–14], indicating the reliability of our results.
According to the results of this study, not only postoperative
complications are significantly correlated with long-term out-
come. Univariate testing also showed significant differences in
preoperative risk factors for patient subgroups with and
without complications, indicating some impact. Irrespective of
the degree of complication (by analyzing all complications,
complication grades 3 and 4 according to the Clavien–Dindo
classification, and complications requiring repeat surgery), a
significant impact of comorbidities and age was notable. This
was evident in univariate analyses in all three comparisons, but
also using a Cox proportional hazards model, as long as the
complete study population was analyzed. To this point, our
results are absolutely in line with the studies from Japan.
However, a long-term observation seems to make more sense if
the effect of early, perioperative mortality is eliminated as these
patients have no influence on long-term survival or disease
recurrence. However, the mentioned studies included this
subgroup of patients (Clavien–Dindo grade 5), which is shown
either by separating the patient subgroup in a Kaplan–Meier
subanalysis [14] or by the drop of the survival curves within
month 0 and the missing significance when grade 5 compli-
cations are eliminated [13].
By elimination of the perioperative mortality from the
analysis in our study for all calculations, the significant
effect of ‘postoperative complications’ on long-term over-
all and recurrence-free survival existed as a visible trend in
Kaplan–Meier plots; however, it failed to qualify as an
independent predictor of survival.
Instead, preoperative comorbidities showed increased
capacity as potential outcome predictors. We identified the
CCI as a significant factor decreasing survival following
liver resection in an HCC cohort. The relevance of this
index [32] as a prognostic factor for long-term survival has
been shown in patients with stage 4 HCC with extra-
hepatic metastases as well as in patients with liver cirrhosis
Fig. 4. Recurrence-free survival. Kaplan–Meier plots of recurrence-free
survival comparing the groups with or without complications at all (a), with
our without complication grades 3 and 4 according to the Clavien–Dindo
classification (b), and comparing those requiring revision surgery or not (c).
Dashed curve: patients without complications; solid curve: patients with
complications.
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following surgical procedures [16,33]. However, studies
analyzing long-term recurrence-free survival in relation to
earlier complications did not focus on the assessment of
pre-existing comorbidities. Furthermore, following liver
resection for various indications, our group was previously
able to prove the significance of comorbidities for long-
term overall survival [34,35]. Recent studies from Taiwan
and Nanjing also discussed the use of the CCI in the
context of liver resection for HCC. A particular advantage
is proposed for the preoperative evaluation of elderly
patients as, besides other comorbidities, age constitutes
one of the variables included in the index [8,9].
Nevertheless, despite an equal study focus, the mentioned
studies on long-term (recurrence-free) survival in relation to
early complications are not completely comparable with each
other. Furthermore, they may not be comparable to a study
from Europe as high disparities in the epidemiology and
incidence of liver cirrhosis and HCC exist [20,36]. In addi-
tion, comorbidities, such as risk factors associated with an
elevated BMI and the incidence of NAFLD, may be more
frequent in Europe, triggered by regional nutritional habits
[37,38]. The underlying reasons are difficult to analyze, but
may be found in the different racial susceptibility to diseases
defining comorbidity [39,40]. Furthermore, the genesis of
HCC in the Asian population may not be comparable to that
in Europe. Whereas nutritive toxic factors may play a key
role in Western countries [37], Asian studies attribute HCC
to hepatitis B and C infection in up to 50% of patients in
surgically treated cohorts [14,36]. In other words, a fictitious
patient with HCC of the same size, differentiation, and
intrahepatic location may not experience the same risk of
complications and recurrence in Asia compared with Europe.
Therefore, it seemed of particular value to carry out a study
on the impact of postoperative complications on recurrence-
free survival outside of Asia. In our cohort, obesity was
present in more than 60%, the median BMI was 26, 24%
had a history of cardiac disease, and diabetes was present in
one-third of our patients (Rentsch M, unpublished data). The
cumulation of comorbidities resulted in a median ASA score
of 3 (indicating severe systemic disturbance from any cause
or causes) and a median CCI of 7 (indicating a severe risk of
mortality). An elevated BMI of greater than 25 has been
reported to improve the prognosis in HCC patients [41];
however, it may increase the surgical risk [22,23].
Cardiopulmonary complications, which are not related to
technical problems, accounted for one-fifth of the complete
spectrum in our cohort; moreover, more than half of the
complications were comorbidity associated. These numbers
reconfirm observations of a study by Schroeder et al. [15],
who tested several scores in terms of their predictive value for
posthepatectomy morbidity and mortality.
Different from other variables of comorbidity, the pre-
operative MELD score was close to normal in our cohort.
This is in line with the center’s policy that liver function
impairment does not have to exceed the Child A stage
before resection. This composition of risk factors, which
was significantly different in patients with versus without
complications, may explain why comorbidities had a
higher impact in multivariate analysis in our cohort com-
pared with previous reports [14].
Perioperative complications and comorbidities might
potentially influence the choice of treatment strategy for
recurrent HCC and in this way affect overall and
recurrence-free survival. To assess this issue, we examined
all recurrence cases [84 (45%) patients] in our patient
cohort. In terms of perioperative complications, we found
that these had no impact on the treatment choice for HCC
recurrence. In fact, most of the patients developed tumor
recurrence after 1 year and longer upon surgery
(16.2 ± 1.8 months; median: 11.8 months). At this time
point, they have usually completely recovered from sur-
gery irrespective of perioperative complications. In terms
of comorbidities, we observed that the CCI and the ASA
score did not differ between the complete study cohort
(CCI: 7.19 ±0.1, ASA: 2.72 ± 0.3) and the patients with
recurrent HCC (CCI: 7.17 ±0.2, ASA: 2.71 ± 0.05). Thus,
comorbidities did not affect the decision of the treatment
strategy for the treatment of recurrent HCC in our cohort.
Conclusion
Our study confirms previous data from Asian single-center and
multicenter studies investigating outcomes after liver resection
for HCC. Overall and recurrence-free survival may be affected
by perioperative complications also in Europe, where comor-
bidities may have a stronger impact on postoperative recovery
in general and in patients with HCC in particular as the
pathogenesis of this malignancy involves triggers that also
promote comorbidity. After elimination of the effects of
immediate perioperative mortality, the CCI was an indepen-
dent factor associated with long-term overall and recurrence-
free survival. Future studies from Europe would have to
evaluate whether the preoperative determination of comor-
bidity indexes is useful in identifying subgroups of patients with
Table 5. Coxproportional hazard model of clinical characteristics on recurrence-free survival
Overall survival (without perioperatively deceased) Recurrence-free survival (without perioperatively deceased)
95% Confidence interval 95% Confidence interval
Variables P Exp (β) Lower limit Upper limit P Exp (β) Lower limit Upper limit
ASA 0.619 1.148 0.665 1.982 0.603 1.153 0.675 1.970
MELD 0.979 1.001 0.905 1.108 0.720 1.018 0.923 1.123
Charlson Comorbidity Index 0.019 1.175 1.027 1.344 0.042 1.149 1.005 1.313
BMI 0.544 0.981 0.922 1.044 0.337 0.969 0.909 1.033
Intraoperative blood loss (ml) 0.847 1.000 1.000 1.000 0.796 1.000 1.000 1.000
Complications (yes/no) 0.248 1.336 0.817 2.184 0.159 1.428 0.870 2.343
Complication grades 3 and 4 0.919 0.964 0.472 1.969 0.630 0.816 0.356 1.868
Septic complications 0.159 0.605 0.301 1.217 0.538 0.802 0.397 1.621
Surgical revision 0.995 1.003 0.375 2.685 0.621 1.214 0.562 2.624
ASA, American Society of Anesthesiologists; MELD, Model for End-Stage Liver Disease.
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beneficial or adverse long-term outcomes following liver
resection for HCC.
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